VCH-916 - CAS 1200133-34-1
Catalog number: 1200133-34-1
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C26H36KNO4S
Molecular Weight:
497.73
COA:
Inquire
Targets:
HCV
Description:
VCH-916 is a novel allosteric inhibitor of HCV NS5B polymerase. The RNA-dependent RNA polymerase (NS5B) of HCV is one of the attractive validated targets for development of new drugs to block HCV infection. VCH-916 is currently being evaluated for safety/tolerability, pharmacokinetics and anti-viral efficacy in chronically infected HCV patient.
Purity:
>98%
Synonyms:
VCH916; VCH 916
MSDS:
Inquire
InChIKey:
RYXIBQLRUHDYEE-UHFFFAOYSA-M
InChI:
InChI=1S/C26H37NO4S.K/c1-17-8-10-19(11-9-17)25(28)27(20-12-14-21(31-2)15-13-20)22-16-23(32-24(22)26(29)30)18-6-4-3-5-7-18;/h6,16-17,19-21H,3-5,7-15H2,1-2H3,(H,29,30);/q;+1/p-1
Canonical SMILES:
CC1CCC(CC1)C(=O)N(C2CCC(CC2)OC)C3=C(SC(=C3)C4=CCCCC4)C(=O)[O-].[K+]
1.Current race in the development of DAAs (direct-acting antivirals) against HCV.
De Clercq E Biochem Pharmacol. 2014 Jun 15;89(4):441-52. doi: 10.1016/j.bcp.2014.04.005. Epub 2014 Apr 13.
The direct-acting antivirals (DAAs) currently in development for treatment of hepatitis C fall into four categories: (i) NS3/4A protease inhibitors: ABT-450/r, faldaprevir, asunaprevir, GS-9256, vedroprevir (GS-9451), danoprevir, MK-5172, vaniprevir, sovaprevir, ACH-2684, narlaprevir and simeprevir, in addition to those that are already developed [telaprevir (Incivek®) and boceprevir (Victrelis®)], (ii) NS5A protein inhibitors: ABT-267, daclatasvir, ledipasvir, ACH-2928, ACH-3102, PPI-668, AZD-7295, MK-8742, and GSK 2336805; (iii) NS5B (nucleoside-type) polymerase inhibitors: sofosbuvir (now approved by the FDA since 6 December 2013), GS-0938, mericitabine, VX-135, ALS 2158 and TMC 649128; (iv) NS5B (non-nucleoside-type) polymerase inhibitors: VX-222, ABT-072, ABT-333, deleobuvir, tegobuvir, setrobuvir, VCH-916, VCH-759, BMS-791325 and TMC-647055. Future drug combinations will likely exist of two or more DAAs belonging to any of the 4 categories, with the aim to achieve (i) pan-genotypic hepatitis C virus (HCV) activity, (ii) little or no risk for resistance; (iii) short duration (i.e. 12 weeks) of treatment, and (iv) a sustained viral response (SVR) and definite cure of the disease.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related HCV Products


CAS 1502655-48-2 Ledipasvir diacetone

Ledipasvir diacetone
(CAS: 1502655-48-2)

Against JFH1/3a-NS5A, DCV was more potent (EC(50) = 0.52 nM) than GS-5885 (EC(50) = 141 nM). DCV sensitivity was increased against JFH1/3a-NS5A-M28V (EC50 = 0.0...

CAS 1441674-54-9 Ledipasvir acetone

Ledipasvir acetone
(CAS: 1441674-54-9)

Ledipasvir is an inhibitor of hepatitis C virus NS5A.

CAS 1425038-27-2 MK-5172 sodium salt

MK-5172 sodium salt
(CAS: 1425038-27-2)

In biochemical assays, MK-5172 was effective against a panel of major genotypes and variants engineered with common resistant mutations observed in clinical stu...

CAS 1377049-84-7 Velpatasvir

Velpatasvir
(CAS: 1377049-84-7)

Velpatasvir is a selective Hepatitis C virus NS 5 protein inhibitor originated by Gilead Sciences. It showed pan-genotypic activity and a high barrier to resist...

CAS 394730-60-0 Boceprevir

Boceprevir
(CAS: 394730-60-0)

An NS3 serine protease inhibitor of hepatitis C virus, for the treatment of HCV infection.

CAS 1206524-86-8 MK-5172 potassium salt

MK-5172 potassium salt
(CAS: 1206524-86-8)

In biochemical assays, MK-5172 was effective against a panel of major genotypes and variants engineered with common resistant mutations observed in clinical stu...

CAS 1502654-87-6 Ledipasvir D-tartrate

Ledipasvir D-tartrate
(CAS: 1502654-87-6)

Against JFH1/3a-NS5A, DCV was more potent (EC(50) = 0.52 nM) than GS-5885 (EC(50) = 141 nM). DCV sensitivity was increased against JFH1/3a-NS5A-M28V (EC50 = 0.0...

CAS 958002-33-0 Beclabuvir

Beclabuvir
(CAS: 958002-33-0)

Beclabuvir is a potent, non-nucleotide inhibitor of HCV NS5B which is currently in Phase III clinical trials for the treatment of chronic HCV infection. Beclabu...

Chemical Structure

CAS 1200133-34-1 VCH-916

Quick Inquiry

Verification code

Featured Items